- Chinese Province To Require Couples To Receive HIV Tests Before Marriage By : HIV / AIDS News
China's Yunnan Province beginning Jan. 1, 2007, will require couples to receive HIV tests before getting married, Xinhua/People's Daily reports. People who test positive for the virus will be required to inform their partners or the local authorities will do so, Xinhua/People's Daily reports (Xinhua/People's Daily, 12/2). - Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows 100% Seroprotection Regardless Of Vaccination Sched By : Hepatitis News
Dynavax Technologies Corporation (Nasdaq: DVAX) announced today positive results from a Phase 2 trial comparing two different vaccination schedules of HEPLISAV, its hepatitis B virus (HBV) vaccine. - Bayer Diagnostics And Innogenetics Launch Versant HCV Genotype 2.0 Assay (LiPA) For Hepatitis C By : Hepatitis News
Bayer HealthCare, Diagnostics Division, a member of the Bayer Group (NYSE:BAY) and Innogenetics N.V. announced today that the VERSANT® HCV (Hepatitis C Virus) Genotype 2.0 Assay (LiPA) has been released for sale in Europe. This next generation hepatitis C assay is an upgrade of Bayer's VERSANT HCV Genotype 1.0 Assay (LiPA), which is considered to be the most widely used assay for HCV Genotyping. - Drug Treats 'Water Intoxication' Faster, More Effectively By : Hepatitis News
Results of the two largest studies on hyponatremia, SALT-1 and SALT-2, presented Nov. 14 at the American Heart Association's Scientific Sessions in Chicago, found that the investigational drug tolvaptan treated hyponatremia - water intoxication -- faster and more effectively than available treatments. - American Thoracic Society Publishes New Statement On Hepatotoxicity Of Antituberculosis Therapy By : Hepatitis News
The American Thoracic Society (ATS) has published a new statement on the pathogenesis, prevention and treatment of liver damage caused by anti-tuberculosis (TB) medications. - Phase I Study Of Novel Gene Therapy For HIV By : HIV / AIDS News
VIRxSYS Corporation announced 6-Nov-2006 the publication of results from their Phase I, open-label, non-randomized clinical trial evaluating VRX496, a gene-based immunotherapy for the treatment of HIV. - Maxygen's Next-Generation Interferon Alpha Enters Phase Ia Clinical Trial By : Hepatitis News
Maxygen, Inc. (Nasdaq: MAXY) announced today that Roche has initiated a Phase Ia clinical trial in New Zealand to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of Maxy-alpha, a next-generation interferon alpha for the treatment of hepatitis C virus infection. - Interaction Between Lymph And Liver Cells May Affect Immune Response By : Hepatitis News
A new study on the ability of liver cells to interact with T cells (lymph cells that play a role in regulating the immune response) found that such interactions do occur and demonstrated the mechanism by which they may take place. The results may help explain the altered immune responses that occur with aging and other conditions and may be useful in developing therapies for viral hepatitis and autoimmune diseases. - Lower Risk Of Reinfection After Recovery From Hepatitis C By : Hepatitis News
A new study found that individuals who had tested positive for hepatitis C (HCV) but later tested negative for the virus were significantly less likely to become infected again compared to those who had never been infected, even though they had the same exposure risks. - Eltrombopag Significantly Improved Platelet Count And Allowed Initiation Of Antiviral Therapy By : Hepatitis News
GlaxoSmithKline plc [NYSE:GSK, LSE:GSK] today announced results from a global Phase II study of eltrombopag, an investigational non-peptide oral platelet growth factor. In this study of 74 hepatitis C patients with thrombocytopenia, (a condition where the blood has low platelet levels) more than 95% (p< 0.001) of patients treated with the highest dose of eltrombopag (75mg) had increased platelet counts. - Making Headway Against Hepatitis C: New Drug Combo Effective In Non-Responders By : Hepatitis News
Saint Louis University Liver Center scientists are presenting research today on a more effective way to treat hepatitis C patients who have been unresponsive to current drug therapies. - Three-Year Data Showed Low Incidence Of BARACLUDE® (Entecavir) Resistance In Nucleoside-Naïve By : Hepatitis News
Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE® (entecavir) resistance monitoring program, which found the incidence of resistance to be low among patients treated with BARACLUDE in nucleoside-naïve studies (n=673). - Tyzeka(TM) Receives US Regulatory Approval As A New Treatment For Patients With Chronic Hepatitis B By : Hepatitis News
Novartis announced today the US regulatory approval of Tyzeka(TM) (telbivudine) as a new once-a-day oral treatment for patients with chronic hepatitis B, a disease estimated to affect about 1.25 million people in the US but more than 350 million globally and considered the tenth leading cause of death. - New Drug Helps Hepatitis C Patients Start Antiviral Therapy By : Hepatitis News
A new drug that stimulates the production of blood platelets can enable patients infected with hepatitis C virus to take other antiviral medications they previously could not take to fight the disease, according to the results of a clinical trial led by a Duke University Medical Center researcher. - Customizing Treatment with PEGASYS® May Improve Chances for Success in Hepatitis C By : Health News
Patients with chronic hepatitis C who respond quickly to PEGASYS® (peginterferon alfa-2a) and COPEGUS® (ribavirin, USP) may have an excellent chance of achieving treatment success with a shortened course of therapy, according to interim results presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Three-quarters of patients with the difficult-to-treat viral genotypes 1 and 4 who had a rapid viral response (RVR) – defined as undetectable levels - Roche Oral Polymerase Inhibitor R1626 Shows Strong Antiviral Activity in Chronic Hepatitis C Patient By : Health News
New clinical data on the hepatitis C polymerase inhibitor R1626 – currently in development by Roche – show viral reductions greater than those described for other polymerase inhibitors, according to data presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). These results were achieved in chronic hepatitis C patients infected with the difficult-to-treat genotype 1 virus. - Human Genome Sciences Reports Positive Interim Results Of Phase 2 Trials Of Albuferon(TM) By : Hepatitis News
Human Genome Sciences, Inc. (Nasdaq: HGSI) today reported the interim results of two Phase 2 clinical trials to evaluate the efficacy and safety of Albuferon(TM) (albumin- interferon alpha 2b) in combination with ribavirin in patients with chronic hepatitis C. The interim results were presented in Boston at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). - Three-Year Data Showed Low Incidence Of BARACLUDE(R) (Entecavir) Resistance In Nucleoside-Naive By : Hepatitis News
Bristol-Myers Squibb Company (NYSE: BMY) today announced three-year results of the BARACLUDE(R) (entecavir) resistance monitoring program, which found the incidence of resistance to be low among patients treated with BARACLUDE in nucleoside-naive studies (n=673). - BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression To Undetectable Levels In Most Patients By : Hepatitis News
Bristol-Myers Squibb Company (NYSE: BMY) today announced data from a three-year cohort (ETV-022/901, n=119), which showed BARACLUDE(R) (entecavir) suppressed viral load to undetectable levels in 90 percent of nucleoside-naive chronic hepatitis B e-antigen (HBeAg) positive patients at week 144 who continued on-treatment from week 96. - New Data From Largest U.S. Hepatitis C Trial Provide Insights Into Optimizing Treatment For Patient By : Hepatitis News
New data from the WIN-R trial, the largest hepatitis C study ever conducted in U.S. patients, provide important insights into optimizing treatment with peginterferon alfa-2b (PEG-INTRON(R), Schering-Plough) and ribavirin (REBETOL(R), Schering-Plough) combination therapy in patient populations traditionally considered difficult to treat. - Study Shows Treatment With BARACLUDE(R) (Entecavir) Resulted In Greater Viral Load By : Hepatitis News
Bristol-Myers Squibb Company (NYSE: BMY) today announced results of an open-label, randomized study of 65 antiviral naive chronic hepatitis B e-antigen (HBeAg) positive patients, showing that patients receiving the oral antiviral therapy BARACLUDE(R) (entecavir) demonstrated greater viral load reduction at weeks 12 (primary endpoint) and 24 than patients treated with adefovir. - TYZEKA(TM) (telbivudine) Approved By U.S. Food And Drug Administration (FDA) As A New Treatment By : Hepatitis News
Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) today announced the approval of TYZEKA(TM) (telbivudine) by the U.S. Food and Drug Administration (FDA) as a new once-a-day oral treatment, taken with or without food, for patients with chronic hepatitis B (CHB). TYZEKA rapidly and profoundly(1) suppresses the hepatitis B virus (HBV) in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. - ViroPharma And Wyeth Initiate Dosing In Phase 2 Study Of HCV-796 In Treatment Naive Patients By : Hepatitis News
ViroPharma Incorporated (Nasdaq: VPHM) today announced that patient dosing has commenced in a Phase 2 study of HCV-796, a unique orally dosed hepatitis C viral polymerase inhibitor that interferes with the replication of hepatitis C virus (HCV). The Phase 2 study is being conducted with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), ViroPharma's partner in development of HCV-796. - Scottish Medicines Consortium (SMC) To Accept Baraclude® (entecavir) For Use Within NHS By : Hepatitis News
Bristol-Myers Squibb Pharmaceuticals Limited (Bristol-Myers Squibb) has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Baraclude® (entecavir) for use within NHS Scotland for the treatment of chronic hepatitis B virus infection. - Tacere Therapeutics Secures Financing And Resumes Development Of RNAi Hepatitis C Drug By : Hepatitis News
Tacere Therapeutics, Inc., an innovative biotechnology company specializing in the development of both traditional and novel therapeutics to treat serious infectious diseases, announced today that the company has secured an undisclosed amount of seed financing from Hokkaido Venture Capital, and has thus established operations and resumed preclinical development of TT-033i, its lead candidate for the treatment of Hepatitis C (HCV). - AVI BioPharma Reports Results on Hepatitis C Virus Clinical Trial By : Health News
AVI BioPharma, Inc. (Nasdaq:AVII) reported results today from the second phase of its multicenter study in patients with chronic active hepatitis C virus (HCV) infection. The second phase of this exploratory trial was designed to assess the safety, tolerability, pharmacokinetics (PK), and viral and clinical response to treatment with AVI’s proprietary NEUGENE® antisense compound, AVI-4065, in HCV patients. - Higher Levels Of Cells Originating In Bone Marrow May Be Useful In Prognosis Of Liver Cancer By : Hepatitis News
A new study found that higher levels of specialized blood cells that originate in bone marrow may potentially be used as a prognostic marker in liver cancer. - Non-Alcoholic Fatty Liver Disease Long-term Effects By : Hepatitis News
A new study found that patients with non-alcoholic fatty liver disease (NAFLD) had a significant risk of developing end-stage liver disease and a lower chance of survival if they had non-alcoholic steatohepatitis (NASH), a form of NAFLD that can lead to cirrhosis. The study also found that most NAFLD patients will eventually develop diabetes or impaired glucose tolerance, which can lead to cardiovascular complications. - Researchers Estimate Significant Non-Alcoholic Fatty Liver Disease In Children By : Hepatitis News
Until now little was known about the prevalence of non-alcoholic fatty liver disease (NAFLD) in children. To gauge its occurrence a University of California, San Diego (UCSD) School of Medicine-led team studied 742 autopsy reports and tissue analysis of San Diego County children aged two to 19 who died from traumatic accidents, homicide or suicide and had a medical examiner autopsy between 1993 and 2003. - Novelos Therapeutics Enrolls 1St Patient in Hepatitis C Trial with NOV-205 By : Health News
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the first patient has been enrolled in a hepatitis C trial with NOV-205, the company’s second compound. - The American Liver Foundation Applauds Steven Tyler For His Frank Discussion About Hepatitis C By : Hepatitis News
The American Liver Foundation (ALF), a national nonprofit organization that provides education, advocacy and research on behalf of the 30 million Americans affected by liver disease, today thanked Steven Tyler, lead singer of Aerosmith, for his recent announcement that he has been battling hepatitis C, a dangerous liver disease that claims 8,000 - 10,000 lives a year in the United States. - Arbios Granted FDA Allowance To Expand SEPET(TM) Clinical Trial Eligibility By : Hepatitis News
Arbios Systems, Inc. (OTC: ABOS) announced today that the U.S. Food & Drug Administration (FDA) has allowed expansion of the eligibility criteria for the ongoing clinical trial of its SEPET(TM) Liver Assist Device to include patients with hepatic encephalopathy due to combined liver and kidney (renal) failure. - World Hepatitis Awareness Day By : Hepatitis News
Copenhagen, Denmark - Sir Bob Geldof today added his voice to that of hepatitis patient groups, the World Health Organization (WHO) Regional Office for Europe and the European Association for the Study of the Liver (EASL) by calling on governments around the world to prioritise hepatitis. - InterMune Submits Clinical Trial Authorization Application For ITMN-191 For Hepatitis C Infections By : Hepatitis News
InterMune, Inc. (Nasdaq: ITMN) announced today that it has submitted an electronic Clinical Trial Authorization (CTA) application to the French Medicinal and Biological Products Evaluation Directorate (AFSSAPS) for ITMN-191, an orally available hepatitis C virus (HCV) protease inhibitor, developed in a collaboration between InterMune research scientists and Array BioPharma, Inc. - Sulphasalazine Can Reverse Liver Disease Even For Heavy Drinkers By : Hepatitis News
Sulphasalazine, a cheap drug currently used for arthritis and IBD (inflammatory bowel disease) can reverse the scarring that comes with cirrhosis of the liver, say scientists from the University of Newcastle, UK. Doctors had always thought that fibrosis - scarring associated with cirrhosis - was irreversible. This new study on animals has shown the damage can be reversed with Sulphasalazine. - Sebivo® Receives First Major Approval In Switzerland As New Treatment For Patients With Chronic By : Hepatitis News
Sebivo® (telbivudine), a new treatment for patients with chronic hepatitis B shown to deliver more rapid and profound viral suppression than lamivudine, has received approval in Switzerland. - Baraclude® (entecavir) Now Available In The UK For Treatment Of Chronic Hepatitis B By : Hepatitis News
Bristol-Myers Squibb announced today that Baraclude® (entecavir) is now available in the UK on prescription for the treatment of chronic hepatitis B virus infection. - Fatty Acids And Caveolin-1 Are Essential In Liver Regeneration By : Hepatitis News
Liver regulates lipid, carbohydrate and protein metabolism. It also segregates a number of proteins and enzymes, and eliminates toxic substances from the organism. Liver regeneration is a mostly unknown process at a molecular level, although it is essential for the good functioning of the liver, and indispensable in order to carry out some therapeutic strategies, such as living-donor transplant. - Cholesterol Implicated In Progression Of Fatty Liver Disease By : Hepatitis News
Cholesterol may play an important role in the progression of fatty liver to an advanced stage of disease that can lead to permanent liver damage, according to a report in the September, 2006 issue of the journal Cell Metabolism, published by Cell Press. The findings suggest that low-cholesterol diets or cholesterol-lowering drugs might offer a useful therapy for the rising epidemic of fatty liver disease. - Despite Early Loss, Bone Mass Continues To Increase In Liver Transplant Patients By : Hepatitis News
A new study on bone loss in patients with liver disease before and after transplant found that those with the lowest bone density before transplant showed the most improvement afterwards. It also showed that bone loss immediately following transplant was common and identified several risk factors for post-transplant bone loss. - NDRI Receives Josiah Macy, Jr. Foundation Grant By : Hepatitis News
NDRI is pleased to announce the receipt of a starter grant from the Josiah Macy, Jr. Foundation to support the implementation and evaluation of a training program on the hepatitis C virus for clinical and non-clinical staff in 5 New York City outpatient drug treatment programs. NDRI investigators have been active in the development of evidence-based training programs intended to enhance the services delivered in drug treatment programs. - Tripep Produces Additional Positive Data for Its Hepatitis C DNA Vaccine Using Inovio's DNA Delivery By : Health News
Inovio Biomedical Corporation (AMEX:INO) announced today that its partner, Tripep AB of Sweden, has achieved additional positive pre-clinical results showing that its ChronVac-C DNA vaccine combined with Inovio's MedPulser(R) DNA delivery system produced a strong immune response against hepatitis C virus (HCV) in a large animal model. - ViroPharma Announces Presentation Of New HCV-796 In Vitro Data At The 13th International Meeting By : Hepatitis News
ViroPharma Incorporated (Nasdaq: VPHM) today announced the presentation of additional preclinical data on HCV-796, an orally dosed non-nucleoside hepatitis C virus (HCV) polymerase inhibitor being co-developed with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), at the 13th International Meeting on Hepatitis C Virus & Related Viruses in Cairns, Australia. - ViroPharma Announces Positive Data From Phase 1b Combination Study Of HCV-796 And Pegylated By : Hepatitis News
ViroPharma Incorporated today announced preliminary data from a Phase 1b study of HCV-796, a unique, orally dosed hepatitis C virus (HCV) polymerase inhibitor being co-developed with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE). Preliminary antiviral data are available in the dose range of 100 mg BID to 1,000 mg BID of HCV-796 dosed over a 14-day period in combination with pegylated interferon alfa-2b. - Minimally Invasive Procedure Can Reduce, Eliminate Benign Liver Tumors By : Hepatitis News
Following extensive patient studies that began in 1999, researchers at Tang Du Hospital, Fourth Military Medical University in Xian, China, have concluded that ultrasound-guided radiofrequency ablation (RFA) can be an efficient and safe method for the treatment of hepatic primary cysts. - Delcath Systems Announces A New Site For The Phase III Doxorubicin Clinical Trial In San Antonio, TX By : Hepatitis News
Delcath Systems, Inc. (Nasdaq: DCTH) ("Company") announced today that the Methodist Health Care System ("Site") has joined Delcath's Phase III clinical trial for the treatment of metastatic melanoma that has spread to the liver, using the Delcath system with Doxorubicin, an approved anti-cancer agent.
|
